AIDS blood purifier

Abstract

The invention discloses an AIDS blood purifier, and belongs to the medicine field. The AIDS blood purifier is characterized in that a separator, by which blood cells and plasma are separated, is prepared; by virtue of a hybridoma technique, a hybridoma macrophage cell line, which not only reserves the properties of original macrophages but also achieves indeterminate growth, is prepared and the hybridoma macrophage cell line undergoes amplification; an HIVgp120 and gp41 antibody and an HIVgp120 and gp41 antibody bonded with anti-goat Ig; the prepared materials (the antibodies) are prepared in agar gels; and the hybridoma macrophage cell line is covered by virtue of a high-biocompatibility material, so that the purifier is prepared; the gels are in layered distribution that an antibody titer is decreased from top to bottom and an agarose concentration is increased from top to bottom, wherein the gp120 and gp41 antibodies which are bonded and not bonded with the anti-goat Ig as well as hybridoma macrophage cells are immobilized in the agar gels so as to take an effect on adsorbing the HIV; the prepared purifier is used in combination of the separator and a regulating program; blood participating in extracorporeal circulation is separated into the plasma and the blood cells by virtue of the separator; and the plasma joins with the blood cells after HIV is filtered out by virtue of the purifier, and then the plasma is returned back.

Description

technical field [0001] The invention relates to the preparation and application of an AIDS blood purifier in the medical field, which is mainly used for removing plasma HIV from AIDS patients so as to achieve the purpose of treating AIDS. Background technique [0002] AIDS is an infectious disease caused by human immunodeficiency virus (Human Immunodeficiency Virus, HIV). So far, 208 countries and regions in the world have been seriously threatened by AIDS. About 40 million people have been infected with AIDS, and the death toll has exceeded 20 million. About 6,000 people become AIDS-infected people every day, and more than 300 people die every day. on AIDS. HIV-infected people in China are in a period of rapid growth, and the number has far exceeded 1 million at present. AIDS has become another major infectious disease facing mankind after tumors, cardiovascular and cerebrovascular diseases, tuberculosis, and diabetes, and has become a serious public health and social pro...

AI Technical Summary

Problems solved by technology

However, the antibody cannot contact the virus remaining in the mononuclear macrophage, and the HIV envelope protein is prone to antigenic variation, and the original antibody loses its effect, so that the neutralizing antibody cannot play its due role

During the latent infection stage, the HIV provirus is integrated into the host cell genome, so HIV will not be recognized by the immune system, so it cannot be eliminated by autoimmunity alone

Another very important reason should be that, based on the mechanism of antibody killing and clearing antigens, it is speculated that after the immune antibody binds to the antigen, it will produce an immune effect, either by activating complement to mediate the A1) CC effect to dissolve the cellular antigen, but HIV is not a cellular antigen; either it attracts phagocytes to engulf the antigen through chemotaxis, but HIV is protected and proliferates in the phagocytes instead; or the antibody binds to the antigen to neutralize it, making it lose its infectivity, but the structure of HIV antigens is diverse. Mutations, often making it difficult for antibodies to recognize

[0006] Judging from the current AIDS treatment methods that have been used clinically, the effect is not so ideal: (1) HIV reverse transcriptase inhibitors: can only prevent the infection of susceptible cells that have not been infected with HIV, and have no therapeutic effect on infected cells, and are toxic There are many side effects, including mitochondrial toxicity, myelosuppression, erythrocytic anemia, neutropenia and thrombocytopenia, pancreatitis, and the generation of cross-drug resistance. Drug-resistant variants, resulting in decreased clinical efficacy or failure

(2) HIV protease inhibitors: prone to drug-induced liver injury, lipid metabolism disorders and other side effects and drug resistance

(4) Inhibiting HIV virus entry inhibitors: including blocking the binding of gp120 to CD4, blocking the binding of HIV to coreceptors, acting on gp41 membrane subunits, and acting on CC chemokine receptor 5 (CCR5) on the surface of T lymphocytes to block HIV from entering host cells, but has side effects on the liver and heart

(6) HIV vaccine treatment: Due to the particularity of HIV, such as innate immunity is not enough to resist HIV and its targeted destruction of the immune system, and the virus mutates rapidly, so far no truly safe and effective vaccine has been developed

(7) Gene therapy: HIV gene therapy research has never stopped, including antisense technology, RNA decoy, RNA interference, intracellular antibodies, dominant negative mutants, suicide genes, etc., but gene therapy that has entered phase II clinical trials hardly

[0009] In short, various drugs and biological products cannot effectively kill HIV in the body, and they are expensive and have severe side effects. So far, there is no effective method for the treatment of AIDS, which has become a worldwide problem that cannot be overcome for a long time.

Images